(QGEN) Qiagen - Overview
Stock: Sample Prep Kits, PCR Assays, Instruments, Bioinformatics Software, NGS Panels
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 5.24% |
| Yield on Cost 5y | 4.94% |
| Yield CAGR 5y | 26.95% |
| Payout Consistency | 8.8% |
| Payout Ratio | 107.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.1% |
| Relative Tail Risk | -7.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.79 |
| Alpha | 14.15 |
| Character TTM | |
|---|---|
| Beta | 0.430 |
| Beta Downside | 0.211 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.76% |
| CAGR/Max DD | 0.15 |
Description: QGEN Qiagen January 03, 2026
Qiagen N.V. (NYSE: QGEN) supplies a broad portfolio of “sample-to-insight” technologies that convert biological specimens into molecular data. Its offerings span primary consumables (e.g., nucleic-acid stabilization kits, magnetic-bead extraction), secondary consumables (purification kits), and instruments for nucleic-acid purification, quality control, and automated PCR. The company also markets diagnostic consumables for immune-response testing (TB, post-transplant monitoring), oncology, reproductive health, forensic DNA, and food safety, alongside next-generation sequencing (NGS) panels, library-prep kits, bioinformatics SaaS, and custom genomics services for diagnostics, academia, pharma, and applied-testing markets.
Key recent metrics: QGEN reported FY 2023 revenue of $1.09 billion, up ~12 % YoY, driven by a 22 % surge in its Molecular Diagnostics segment and a 15 % increase in the Life Science Tools division. The firm entered 2024 with a cash-and-cash-equivalents balance of roughly $520 million, supporting its ongoing acquisition pipeline. Sector-wide, the global molecular diagnostics market is projected to grow at a CAGR of ~10 % through 2029, fueled by expanding infectious-disease testing, personalized oncology, and the shift toward decentralized point-of-care platforms-trends that directly benefit Qiagen’s integrated hardware-software solutions.
For a deeper quantitative view of Qiagen’s valuation and risk profile, you might explore the ValueRay platform’s analyst tools.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 424.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.64 > 1.0 |
| NWC/Revenue: 70.95% < 20% (prev 71.59%; Δ -0.64% < -1%) |
| CFO/TA 0.10 > 3% & CFO 654.3m > Net Income 424.9m |
| Net Debt (815.4m) to EBITDA (717.3m): 1.14 < 3 |
| Current Ratio: 3.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (207.8m) vs 12m ago -4.70% < -2% |
| Gross Margin: 61.79% > 18% (prev 0.49%; Δ 6131 % > 0.5%) |
| Asset Turnover: 34.88% > 50% (prev 34.77%; Δ 0.11% > 0%) |
| Interest Coverage Ratio: 15.74 > 6 (EBITDA TTM 717.3m / Interest Expense TTM 33.3m) |
Altman Z'' 4.55
| A: 0.24 (Total Current Assets 2.00b - Total Current Liabilities 512.1m) / Total Assets 6.30b |
| B: 0.44 (Retained Earnings 2.75b / Total Assets 6.30b) |
| C: 0.09 (EBIT TTM 523.5m / Avg Total Assets 5.99b) |
| D: 0.94 (Book Value of Equity 2.37b / Total Liabilities 2.52b) |
| Altman-Z'' Score: 4.55 = AA |
Beneish M -3.34
| DSRI: 0.83 (Receivables 402.6m/459.0m, Revenue 2.09b/1.98b) |
| GMI: 0.79 (GM 61.79% / 48.90%) |
| AQI: 1.03 (AQ_t 0.54 / AQ_t-1 0.52) |
| SGI: 1.06 (Revenue 2.09b / 1.98b) |
| TATA: -0.04 (NI 424.9m - CFO 654.3m) / TA 6.30b) |
| Beneish M-Score: -3.34 (Cap -4..+1) = AA |
What is the price of QGEN shares?
Over the past week, the price has changed by -5.07%, over one month by +14.20%, over three months by +24.68% and over the past year by +27.16%.
Is QGEN a buy, sell or hold?
- StrongBuy: 6
- Buy: 3
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the QGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54.4 | 6.8% |
| Analysts Target Price | 54.4 | 6.8% |
| ValueRay Target Price | 60.1 | 18% |
QGEN Fundamental Data Overview February 07, 2026
P/E Forward = 18.3486
P/S = 5.0963
P/B = 2.9189
P/EG = 0.3462
Revenue TTM = 2.09b USD
EBIT TTM = 523.5m USD
EBITDA TTM = 717.3m USD
Long Term Debt = 1.63b USD (from longTermDebt, two quarters ago)
Short Term Debt = 499.6m USD (from shortTermDebt, two quarters ago)
Debt = 1.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 815.4m USD (from netDebt column, last quarter)
Enterprise Value = 11.11b USD (10.55b + Debt 1.65b - CCE 1.10b)
Interest Coverage Ratio = 15.74 (Ebit TTM 523.5m / Interest Expense TTM 33.3m)
EV/FCF = 24.54x (Enterprise Value 11.11b / FCF TTM 452.6m)
FCF Yield = 4.07% (FCF TTM 452.6m / Enterprise Value 11.11b)
FCF Margin = 21.66% (FCF TTM 452.6m / Revenue TTM 2.09b)
Net Margin = 20.33% (Net Income TTM 424.9m / Revenue TTM 2.09b)
Gross Margin = 61.79% ((Revenue TTM 2.09b - Cost of Revenue TTM 798.5m) / Revenue TTM)
Gross Margin QoQ = 58.71% (prev 62.20%)
Tobins Q-Ratio = 1.76 (Enterprise Value 11.11b / Total Assets 6.30b)
Interest Expense / Debt = 0.61% (Interest Expense 10.1m / Debt 1.65b)
Taxrate = 1.23% (1.34m / 109.2m)
NOPAT = 517.1m (EBIT 523.5m * (1 - 1.23%))
Current Ratio = 3.90 (Total Current Assets 2.00b / Total Current Liabilities 512.1m)
Debt / Equity = 0.44 (Debt 1.65b / totalStockholderEquity, last quarter 3.78b)
Debt / EBITDA = 1.14 (Net Debt 815.4m / EBITDA 717.3m)
Debt / FCF = 1.80 (Net Debt 815.4m / FCF TTM 452.6m)
Total Stockholder Equity = 3.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 424.9m / Total Assets 6.30b)
RoE = 11.85% (Net Income TTM 424.9m / Total Stockholder Equity 3.59b)
RoCE = 10.04% (EBIT 523.5m / Capital Employed (Equity 3.59b + L.T.Debt 1.63b))
RoIC = 9.98% (NOPAT 517.1m / Invested Capital 5.18b)
WACC = 6.57% (E(10.55b)/V(12.21b) * Re(7.50%) + D(1.65b)/V(12.21b) * Rd(0.61%) * (1-Tc(0.01)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.65%
[DCF Debug] Terminal Value 83.37% ; FCFF base≈472.5m ; Y1≈462.8m ; Y5≈470.0m
Fair Price DCF = 51.94 (EV 11.52b - Net Debt 815.4m = Equity 10.70b / Shares 206.0m; r=6.57% [WACC]; 5y FCF grow -3.02% → 2.90% )
EPS Correlation: -12.26 | EPS CAGR: -9.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: -7.44 | Revenue CAGR: -3.94% | SUE: 3.22 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.54 | Chg30d=-0.065 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=2.51 | Chg30d=-0.162 | Revisions Net=-1 | Growth EPS=+5.6% | Growth Revenue=+5.1%
EPS next Year (2027-12-31): EPS=2.84 | Chg30d=-0.098 | Revisions Net=-3 | Growth EPS=+12.9% | Growth Revenue=+6.6%